WO2011130852A1 - Preparation of intermediates for the synthesis of dihydropyridine calcium channel blockers - Google Patents
Preparation of intermediates for the synthesis of dihydropyridine calcium channel blockers Download PDFInfo
- Publication number
- WO2011130852A1 WO2011130852A1 PCT/CA2011/050192 CA2011050192W WO2011130852A1 WO 2011130852 A1 WO2011130852 A1 WO 2011130852A1 CA 2011050192 W CA2011050192 W CA 2011050192W WO 2011130852 A1 WO2011130852 A1 WO 2011130852A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- dimethyl
- dichlorophenyl
- methoxycarbonyl
- dihydro
- Prior art date
Links
- 0 CC(NC(C)=C(C1c2cccc(*)c2*)C(O*)=O)=C1C(O)=O Chemical compound CC(NC(C)=C(C1c2cccc(*)c2*)C(O*)=O)=C1C(O)=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- This invention relates to the preparation and purification of monoesters of 4-aryl-1 ,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, which are key intermediates in the preparation of dihydropyridine calcium channel blockers.
- Dihydropyridine calcium channel blockers are often used to reduce systemic vascular resistance and arterial pressure, and a number of diesters of 4-aryl-1 ,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid are currently marketed worldwide as antihypertensive drugs.
- X, Y are independently selected from hydrogen, halogen or nitro; R 2 £ different from each other and selected from Ci-C 4 alkyl or (CH 2 ) m -OR 3 , where is 1 or 2, and R 3 is selected from Ci-C 4 alkyl or Ci-C 4 acyl.
- Compounds of formula 2 are commonly prepared by basic hydrolysis of cyanoethyl esters of formula 3, which can be in turn prepared via the Knoevenagel-Fries modification of the Hantzsch reaction (condensation of one equivalent of a ⁇ -dicarbonyl compound with one equivalent of an aminocrotonate and one equivalent of an aldehyde).
- the synthesis of intermediates of formula 3 is discussed in detail by Ogawa ⁇ Chem. Pharm. Bull. 1993, 41, 108 and 1994, 42, 1579), and chromatographic purification is required for obtaining pure samples.
- the present invention provides a simple and scalable process for the preparation of substituted dihydropyridine mono-acids of formula 2 of purity suitable for the preparation of API quality unsymmetrically substituted dihydropyridine calcium channel blocker drugs. It comprises a one-pot preparation of crude compound 2, followed by precipitation of its alkali metal salt, essentially free of diacid 5 and salts thereof.
- the carboxylic acid 2 may be regenerated by addition of strong acid such as phosphoric acid, and may be further purified by suspension in a mixture of acetone and heptane. Overall yield for the process is usually greater than 45%, and purity of the produced carboxylic acid 2 is usually greater than 97%.
- Ri is Ci - C 4 alkyl or (CH 2 )m-OR3 where m is 1 or 2 and R 3 is Ci-C 4 alkyl or Ci-C 4 acyl, from a mixture thereof with the corresponding 2,5-diacid, which comprises adding to an aqueous solution of the mixture a source of alkali metal ions so as selectively to precipitate the alkali metal salt of the mono-acid to the substantial exclusion of the diacid and compounds thereof, and separating the precipitate so formed from the aqueous solution.
- Suitable sources of alkali metal ions include sodium chloride, potassium chloride, lithium chloride, sodium hydroxide, potassium hydroxide and lithium hydroxide.
- the invention is exemplified by, but not limited to, preparation of clevidipine butyrate, in which case the mono-acid of formula 2 is 4-(2,3- dichlorophenyl)-1 ,4-dihydro-2,6-dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid.
- the free mono-acid is regenerated from its carboxylate (salt) after separation, by reaction with strong mineral acid, such as sulfuric acid, nitric acid, hydrochloric acid or phosphoric acid, with phosphoric acid being the preferred choice.
- a preferred embodiment of the process of the present invention uses one or more Ci-C 4 lower alcohols as co-solvent to address this problem; the salts of compound 2 are very soluble in such alcohols, but the efficiency of the precipitation is not affected by the presence of the organic solvent. Methanol is particularly preferred. As an additional benefit, use of alcohols also results in the precipitation of a more easily filterable solid. Further purification of the separated solid can be effected by washing with acetone/heptane mixture.
- the mono-acid is alkylated to introduce the desired second, unsymmetrical ester group, in the known way.
- this involves reaction with chloromethyl butyrate.
- Example 3 Synthesis of 3-butanoyloxymethoxycarbonyl-5-methoxycarbonyl-4- (2,3-dichlorophenyl)-2,6-dimethyl-1 ,4-dihydropyridine
- Purified carboxylic acid 2 (5.00g, 14 mmol) and potassium carbonate (1 .94g, 14 mmol) were suspended in a mixture of 1 ,4-dioxane (25ml_) and water (1 .25ml_).
- Chloromethyl butyrate (3.26g, 24 mmol) was added and the reaction mixture was refluxed for 4h.
- the reaction mixture was cooled to room temperature, and heptane (17ml_) and silica gel were added.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Abstract
4- (2,3- dichlorophenyl) -1,4- dihydro- 2,6- dimethyl- 5- methoxycarbonyl- 3- pyridinecarboxylic acid, a key intermediate in the synthesis of the cardiovascular calcium channel blocker drug 3-butanoyloxymethoxycarbonyl-5- methoxycarbonyl-4- (2,3-dichlorophenyl) -2,6- dimethyl-1,4- dihydropyridine, of purity greater than 97% and essentially free of the corresponding diacid, is prepared by a process involving selective precipitation of its carboxylate via addition of concentrated solutions of alkali metal salts. Similar intermediate mono-carboxylic acids useful in the synthesis of other unsymmetrically substituted dihydropyrine drugs such as nisoldipine, nitrendipine and nimodipine can be similarly prepared and purified.
Description
PREPARATION OF INTERMEDIATES FOR THE SYNTHESIS OF DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS
Field of Invention
[0001] This invention relates to the preparation and purification of monoesters of 4-aryl-1 ,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, which are key intermediates in the preparation of dihydropyridine calcium channel blockers.
Background of the Invention and Prior Art
[0002] Dihydropyridine calcium channel blockers are often used to reduce systemic vascular resistance and arterial pressure, and a number of diesters of 4-aryl-1 ,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid are currently marketed worldwide as antihypertensive drugs.
[0003] The synthesis of symmetrical dihydropyridine diesters - such as nifedipine - is accomplished via the Hantzsch reaction (condensation of two equivalents of a β-dicarbonyl compound with one equivalent of an aldehyde in the presence of ammonia), whereas dihydropiridines of formula 1 , having two different ester moieties, have to be prepared by alternative routes.
2
X, Y are independently selected from hydrogen, halogen or nitro; R2 £ different from each other and selected from Ci-C4 alkyl or (CH2)m-OR3, where is 1 or 2, and R3 is selected from Ci-C4 alkyl or Ci-C4 acyl.
[0004] Preparation of compounds of formula 1 by derivatization of carboxylic acid intermediates of formula 2 has been described in both the scientific (J. Org. Chem. 2002, 67, 401 ; Tetrahedron Asymmetry 2001 , 12, 3251 ; J. Chem. Soc.
Perkin Trans. 1 1993, 525; Chem. Pharm. Bull. 1993, 41, 1049; 1993, 41, 1060; 1991 , 39, 108) and patent (EP 1318147; EP 1 191021 ; US 6,350,762; US 6, 133,443; US 5,767, 131 ) literature; notably, both nimodipine (US 4,510,310) and clevidipine (US 5,856,346) are reported to be prepared in this manner. Similar considerations apply to other unsymmetrically substituted dihydropyridine drugs such as nisoldipine and nitrendipine.
[0005] Compounds of formula 2 are commonly prepared by basic hydrolysis of cyanoethyl esters of formula 3, which can be in turn prepared via the Knoevenagel-Fries modification of the Hantzsch reaction (condensation of one equivalent of a β-dicarbonyl compound with one equivalent of an aminocrotonate and one equivalent of an aldehyde). The synthesis of intermediates of formula 3 is discussed in detail by Ogawa {Chem. Pharm. Bull. 1993, 41, 108 and 1994, 42, 1579), and chromatographic purification is required for obtaining pure samples. The reversible nature of the initial steps of the Hantzsch dihydropyridine synthesis leads to the formation of compounds of formula 4 as a side-product, with as much as 6% of the symmetrical product being observed by Knaus (Org. Prep. Proced. Int. 1996, 28, 91 ). The applicant's experiments have shown similar results.
[0006] Upon hydrolysis, compounds of formula 4 generate diacids of formula 5, alkylation of which produces symmetrical diesters of formula 6 as a contaminant in the desired dihydropyridine. The structural similarities between compounds of formula 1 and those of formula 6 generally result in the latter being particularly undesirable impurities, as their removal is quite difficult and can only
be accomplished by multiple crystallizations, at the cost of a significant reduction in yield and associated increase in cost and processing time.
[0007] Despite the problems posed by the formation of diesters of formula 4 during the Hantzsch reaction, no procedures other than column chromatography have thus far been proposed for the purification of intermediates of formulas 2 and/or 3.
[0008] It is an object of the present invention, to provide a novel synthesis of compounds of formula 1 , which involves fewer and simpler purification steps to produce material of pharmaceutical grade.
[0009] It is a further object to provide a novel process for purification of intermediates useful in the synthesis of heterosubstituted diesters of 4-aryl-1 ,4- dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid. Summary of the Invention
[0010] The present invention provides a simple and scalable process for the preparation of substituted dihydropyridine mono-acids of formula 2 of purity suitable for the preparation of API quality unsymmetrically substituted dihydropyridine calcium channel blocker drugs. It comprises a one-pot preparation of crude compound 2, followed by precipitation of its alkali metal salt, essentially free of diacid 5 and salts thereof. The carboxylic acid 2 may be regenerated by addition of strong acid such as phosphoric acid, and may be further purified by suspension in a mixture of acetone and heptane. Overall yield
for the process is usually greater than 45%, and purity of the produced carboxylic acid 2 is usually greater than 97%.
[0011] Thus according to one aspect of the invention, there is provided a process of selectively recovering a substituted 1 ,4-dihydropyridine mono-acid of formula:
2 where X and Y are independently hydrogen, chloro or nitro; Ri is Ci - C4 alkyl or (CH2)m-OR3 where m is 1 or 2 and R3 is Ci-C4 alkyl or Ci-C4 acyl, from a mixture thereof with the corresponding 2,5-diacid, which comprises adding to an aqueous solution of the mixture a source of alkali metal ions so as selectively to precipitate the alkali metal salt of the mono-acid to the substantial exclusion of the diacid and compounds thereof, and separating the precipitate so formed from the aqueous solution.
Description of the Preferred Embodiments
[0012] Suitable sources of alkali metal ions include sodium chloride, potassium chloride, lithium chloride, sodium hydroxide, potassium hydroxide and lithium hydroxide.
[0013] Pronounced and unexpected differences in solubility were observed when concentrated solutions of sodium chloride or an alkaline metal hydroxide were added to solutions of compounds 2 and 5 in basic media. Whereas the acid 2 is precipitated as the corresponding carboxylate, the salt of diacid 5 stays in solution. In this manner, the level of impurity 5 in samples of compound 2 can be reliably reduced to below 0.5%, even when 5 was originally present in as much as 10%.
[0014] The invention is exemplified by, but not limited to, preparation of clevidipine butyrate, in which case the mono-acid of formula 2 is 4-(2,3- dichlorophenyl)-1 ,4-dihydro-2,6-dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid. [0015] Preferably the free mono-acid is regenerated from its carboxylate (salt) after separation, by reaction with strong mineral acid, such as sulfuric acid, nitric acid, hydrochloric acid or phosphoric acid, with phosphoric acid being the preferred choice.
[0016] The relatively low solubility of the salts of carboxylic acid 2 in water leads to volumetrically inefficient processes, which may be deemed unsuitable for scale-up. Accordingly, a preferred embodiment of the process of the present invention uses one or more Ci-C4 lower alcohols as co-solvent to address this problem; the salts of compound 2 are very soluble in such alcohols, but the efficiency of the precipitation is not affected by the presence of the organic solvent. Methanol is particularly preferred. As an additional benefit, use of alcohols also results in the precipitation of a more easily filterable solid. Further purification of the separated solid can be effected by washing with acetone/heptane mixture.
[0017] Availability of a method for the purification of mono-carboxylic acid 2 reduces or even eliminates the need for the purification of reaction intermediates, thus allowing the development of a one-pot procedure for the synthesis of this intermediate 2. The synthetic procedure is particularly suitable for large scale manufacturing; it is volumetrically efficient and does not involve chromatography, temperature extremes or solvent exchanges, with the product being isolated by filtration.
[0018] Following purification, the mono-acid is alkylated to introduce the desired second, unsymmetrical ester group, in the known way. In the case of preparation of clevidipine butyrate, this involves reaction with chloromethyl butyrate.
[0019] The invention is further described, for illustrative purposes, in the following specific, non-limiting experimental examples.
Specific Description of the Most Preferred Embodiment
Example 1 - Synthesis of crude 5-methoxycarbonyl-4-(2,3-dichlorophenyl)-2,6- dimethyl-1 ,4-dihydropyridine-3-carboxylic acid
[0020] The starting materials 2,2,6-trimethyl-4/-/-1 ,3-dioxin-4-one (89.2g, 0.63 mol) and 3-hydroxypropionitrile (44.6g, 0.63 mol) were heated in an oil bath at 120°C for 3h, during which acetone (the reaction byproduct) was distilled off. The reaction mixture was cooled to room temperature, and isopropanol (570ml_), methyl 3-aminocrotonate (65.7g, 0.57 mol) and 2,3-dichlorobenzaldehyde (100.0g, 0.57 mol) were added. The reaction mixture was heated to reflux, and some of the isopropanol (340m L) was distilled off. The reaction mixture was then cooled in an ice-water bath and dichloromethane (230m L) and a solution of NaOH (28.7g, 0.72 mol) in water (290ml_) were added. After stirring at room temperature for several hours, the reaction mixture was diluted with water and the layers were separated. The aqueous phase was extracted once more with dichloromethane, after which it was cooled in an ice-water bath and phosphoric acid (85%, 25ml_) was added. After precipitation and stirring, the solids were collected by filtration and washed with water. Drying under high vacuum at 40°C gave carboxylic acid 2 as a yellow powder (126 g, 62% yield). Analysis by HPLC indicates a purity of 89.23%, with 3.17% of diacid 5 present.
Example 2 - Purification of 5-methoxycarbonyl-4-(2,3-dichlorophenyl)-2,6- dimethyl-1 ,4-dihydropyridine-3-carboxylic acid
[0021] The crude carboxylic acid 2 from Example 1 (126g, 0.35 mol) was dissolved in a mixture of methanol (230ml_) and a solution of NaOH (34. Og, 0.85 mol) in water (230ml_). The solution was extracted with dichloromethane, and brine was added to the aqueous layer. The solids were collected by filtration and then re-suspended in water and stirred vigorously for 2h, after which the reaction
mixture was cooled in an ice-water bath and phosphoric acid (85%, 21 ml_) was added. The solids were collected by filtration and washed with water. After drying under vacuum at 40°C, compound 2 was suspended in a 1 : 1 mixture of acetone and heptane and vigorously stirred for 2h. The solids were collected by filtration and washed with heptane. Drying under high vacuum at 40°C gave carboxylic acid 2 as a beige powder (95 g, 75% yield, 46%overall yield). Analysis by HPLC indicates a purity of 97.28%, with 0.13% of diacid 5 present.
Example 3 - Synthesis of 3-butanoyloxymethoxycarbonyl-5-methoxycarbonyl-4- (2,3-dichlorophenyl)-2,6-dimethyl-1 ,4-dihydropyridine [0022] Purified carboxylic acid 2 (5.00g, 14 mmol) and potassium carbonate (1 .94g, 14 mmol) were suspended in a mixture of 1 ,4-dioxane (25ml_) and water (1 .25ml_). Chloromethyl butyrate (3.26g, 24 mmol) was added and the reaction mixture was refluxed for 4h. The reaction mixture was cooled to room temperature, and heptane (17ml_) and silica gel were added. The solids were filtered off and washed with a mixture of 1 ,4-dioxane and heptane. Isopropanol (20ml_) and water (75ml_) were added to the combined filtrates. The resulting solution was stirred at room temperature and the formed solids were collected by filtration and washed with a mixture of water and isopropanol followed by heptane. Drying for 48h under high vacuum at 40°C gave the title compound as an off-white powder (4.20g, 66% yield). Analysis by HPLC indicates a purity of 99.03%, with no impurity 6 being detected.
Claims
1 . A process of selectively recovering a substituted 1 ,4-dihydropyridine mono- acid of formula:
2 where X and Y are independently hydrogen, chloro or nitro; Ri is Ci-C4 alkyl or (CH2)m-OR3 where m is 1 or 2 and R3 is Ci-C4 alkyl or Ci-C4 acyl, from a mixture thereof with the corresponding 2,5-diacid, which comprises adding to an aqueous basic solution of the mixture a source of alkali metal ions so as selectively to precipitate the alkali metal salt of the mono-acid to the substantial exclusion of the diacid and compounds thereof, and separating the precipitate so formed from the aqueous solution.
2. The process of claim 1 , wherein the mono-acid is reformed after separation by reaction with strong acid.
3. The process of claim 2 wherein the strong acid is phosphoric acid.
4. The process of claim 2 wherein the source of alkali metal ions is sodium chloride, potassium chloride, lithium chloride, sodium hydroxide, potassium hydroxide or lithium hydroxide.
5. The process of claim 4 wherein the source of alkali metal ions is sodium chloride.
6. The process of claim 1 wherein the aqueous solution of the mixture includes at least one Ci-C alcohol co-solvent.
7. The process of claim 6 wherein the volumetric ratio of water to alcohol in the aqueous solution is in the approximate range 3:7 to 7:3.
8. The process of claim 6 wherein the alcohol is methanol.
9. The process of claim 2 wherein the precipitate is separated by filtration, and the precipitate is further purified by washing with acetone/heptane mixture.
10. The process of claim 1 wherein the mono-acid is 4-(2,3-dichlorophenyl)-1 ,4- dihydro-2,6-dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid and the di-acid is 4-(2,3-dichlorophenyl)-1 ,4-dihydro-2,6-dimethyl-3,5- pyridinedicarboxylic acid.
1 1 . A process for the preparation of 3-butanoyloxymethoxycarbonyl-5- methoxycarbonyl-4-(2,3-dichlorophenyl)-2,6-dimethyl-1 ,4-dihydropyridinei which comprises:
a. reacting 2-cyanoethyl acetoacetate with methyl 3-aminocrotonate and 2,3-dichlorobenzaldehyde to produce the 2-cyanoethyl ester of 4-(2,3-dichlorophenyl)-1 ,4-dihydro-2,6-dimethyl-5-methoxycarbonyl- 3-pyridinecarboxylic acid;
b. hydrolyzing the 2-cyanoethyl ester of 4-(2,3-dichlorophenyl)-1 ,4- dihydro-2,6-dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid with base to produce the corresponding carboxylate; c. selectively precipitating 4-(2,3-dichlorophenyl)-1 ,4-dihydro-2,6- dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid as its sodium salt by neutralization of the reaction mixture with a base and addition of a source of sodium ions; d. recovering the precipitated 4-(2,3-dichlorophenyl)-1 ,4-dihydro-2,6- dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid by filtration; and
e. reacting this pyridinecarboxylic acid with chloromethyl butyrate.
12. The process of claim 1 1 wherein the selective precipitation takes place from an aqueous medium containing a Ci-C4 alcohol co-solvent.
13. The process of claim 12 wherein the co-solvent is methanol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2701272 CA2701272A1 (en) | 2010-04-21 | 2010-04-21 | Preparation of intermediates for the synthesis of dihydropyridine calcium channel blockers |
CA2,701,272 | 2010-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011130852A1 true WO2011130852A1 (en) | 2011-10-27 |
Family
ID=44833598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2011/050192 WO2011130852A1 (en) | 2010-04-21 | 2011-04-12 | Preparation of intermediates for the synthesis of dihydropyridine calcium channel blockers |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2701272A1 (en) |
WO (1) | WO2011130852A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103086956A (en) * | 2013-01-17 | 2013-05-08 | 北京嘉林药业股份有限公司 | Purification method of clevidipine butyrate intermediate |
CN105198797A (en) * | 2015-11-12 | 2015-12-30 | 华仁药业股份有限公司 | Purification method of clevidipine butyrate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4285955A (en) * | 1978-10-31 | 1981-08-25 | Bayer Aktiengesellschaft | 1,4-Dihydropyridinecarboxylic acids |
US5234821A (en) * | 1990-09-01 | 1993-08-10 | Kazuo Achiwa | Process for preparing 1,4 dihydropyridine compounds |
CA2349195A1 (en) * | 1998-11-23 | 2000-06-02 | Astrazeneca Ab | New manufacturing process |
-
2010
- 2010-04-21 CA CA 2701272 patent/CA2701272A1/en not_active Abandoned
-
2011
- 2011-04-12 WO PCT/CA2011/050192 patent/WO2011130852A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4285955A (en) * | 1978-10-31 | 1981-08-25 | Bayer Aktiengesellschaft | 1,4-Dihydropyridinecarboxylic acids |
US5234821A (en) * | 1990-09-01 | 1993-08-10 | Kazuo Achiwa | Process for preparing 1,4 dihydropyridine compounds |
CA2349195A1 (en) * | 1998-11-23 | 2000-06-02 | Astrazeneca Ab | New manufacturing process |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103086956A (en) * | 2013-01-17 | 2013-05-08 | 北京嘉林药业股份有限公司 | Purification method of clevidipine butyrate intermediate |
CN103086956B (en) * | 2013-01-17 | 2015-11-04 | 北京嘉林药业股份有限公司 | A kind of purification process of clevidipine butyrate intermediate |
CN105198797A (en) * | 2015-11-12 | 2015-12-30 | 华仁药业股份有限公司 | Purification method of clevidipine butyrate |
Also Published As
Publication number | Publication date |
---|---|
CA2701272A1 (en) | 2011-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7482464B2 (en) | Processes for the preparation of S-(-)-amlodipine | |
CN101316820B (en) | Process for preparation of chiral amlodipine gentisate | |
EP1831166B1 (en) | Optical resolution method of amlodipine | |
WO2011130852A1 (en) | Preparation of intermediates for the synthesis of dihydropyridine calcium channel blockers | |
KR100488384B1 (en) | New Manufacturing Process | |
KR100374767B1 (en) | Improved method of preparing amlodipine | |
CA2701087A1 (en) | Preparation of clevidipine butyrate ring the same | |
EP1532110B1 (en) | Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine) | |
KR100989970B1 (en) | Resolution method of S---amlodipine | |
KR101152608B1 (en) | Optical resolution method of (R)- or (S)-amlodipine isomer from (R,S)-amlodipine mixture | |
JP4544895B2 (en) | Method for producing dihydropyridine derivatives | |
KR101294702B1 (en) | process for preparing S-(-)-amlodipine.HCl | |
WO2006022488A1 (en) | Process for purification of cilostazol | |
JP2010189293A (en) | Method for producing 1,4-dihydropyridine derivative | |
CA2148421C (en) | Process for producing optically pure 1,4-dihydropyridines | |
KR0148125B1 (en) | Processes for the preparation of 1,4-dihydropyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11771457 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11771457 Country of ref document: EP Kind code of ref document: A1 |